Intralesional therapy for metastatic melanoma

Bibliography

• Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol 2014;109:327-31
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48
   PubMed Web of Science ®Google Scholar
• Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:395-407
   PubMed Web of Science ®Google Scholar
• Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007;245:591-6
   PubMed Web of Science ®Google Scholar
• Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012;19:1637-43
   PubMed Web of Science ®Google Scholar
• Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011;104:391-6
   PubMed Web of Science ®Google Scholar
• Coley WB. The treatment of malignant tumors by repeated innoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;10:487-511
   Google Scholar
• Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907;i:927-33; 96-1003
   Google Scholar
• Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep 2007;9:417-27
   Google Scholar
• Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin North Am 2014;94(5):1003-15
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross MI, Delman K, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM Study and the Contribution of Surgery to Response [abstract 52]. SSO; 12 – 15 March 2014; Phoenix, Arizona
   Google Scholar
• Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013;31(Suppl):abstract LBA9008
   Google Scholar
• Sarnaik AA, Crago G, Liu H, et al. Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol 2014;32(5s Suppl):abstract 9028
   Google Scholar
• Agarwala SS, Thompson JF, Smithers BM, et al. Chemoablation of metastatic melanoma with rose bengal (PV-10). J Clin Oncol 2010;28(15_suppl):abstract 8534
   Google Scholar
• Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol 2014;109:320-6
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010;20:218-26
   PubMed Web of Science ®Google Scholar
• Green DS, Bodman-Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-45
   PubMed Web of Science ®Google Scholar
• Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010;116:4139-46
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008;8:839-44
   PubMed Web of Science ®Google Scholar
• Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-9
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-9
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16:521-6
   PubMed Web of Science ®Google Scholar
• Richards J, Thompson J, Atkins MB, et al. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 2002;21:346a
   Google Scholar
• Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149:17-21
   PubMedGoogle Scholar
• Seigler HF, Shingleton WW, Pickrell KL. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. Plast Reconstr Surg 1975;55:294-8
   PubMed Web of Science ®Google Scholar
• Cohen MH, Elin RJ, Cohen BJ. Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother 1991;32:315-24
   PubMed Web of Science ®Google Scholar
• Robinson JC. Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 1977;9:587-93
   PubMed Web of Science ®Google Scholar
• Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998;77:2336-42
   PubMed Web of Science ®Google Scholar
• Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013;39:4-16
   PubMed Web of Science ®Google Scholar
• Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83:148-57
   PubMed Web of Science ®Google Scholar
• Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005;15:45-51
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, et al. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001;32:273-6
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17:718-30
   PubMed Web of Science ®Google Scholar
• Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-22
   PubMed Web of Science ®Google Scholar
• Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247-55
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001;15:218-23
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
   PubMed Web of Science ®Google Scholar
• Choi KJ, Kim JH, Lee YS, et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006;13:1010-20
   PubMed Web of Science ®Google Scholar
• Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16:542-6
   PubMed Web of Science ®Google Scholar
• Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 1984;3:491-500
   Google Scholar
• Dummer R, Rochlitz C, Velu T, et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008;16:985-94
   Google Scholar
• Garcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011;21:235-43
   PubMed Web of Science ®Google Scholar
• Green DS, Dalgleish AG, Belonwu N, et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008;159:606-14
   PubMed Web of Science ®Google Scholar
• Tartour E, Mehtali M, Sastre-Garau X, et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 2000;83:1454-61
   PubMed Web of Science ®Google Scholar
• Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr 2009;100:571-85
   PubMedGoogle Scholar
• Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-6
   PubMed Web of Science ®Google Scholar
• Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 2011;104:711-17
   PubMed Web of Science ®Google Scholar
• Tan CY, Neuhaus SJ. Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma. ANZ J Surg 2013;83:93
   Google Scholar
• Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008;18:405-11
   PubMed Web of Science ®Google Scholar
• Delprat GD Jr. Studies on liver function: rose bengal elimination from the blood as influenced by liver injury. Arch Intern Med 1923;32:401-10
   Google Scholar
• Foote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 2010;20:48-51
   PubMed Web of Science ®Google Scholar
• Toomey P, Kodumudi K, Weber A, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One 2013;8:e68561
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Thompson JF, Smithers BM, et al. Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal [abstract]. Ann Oncol 2012;23:Suppl 9
   Google Scholar
• Agarwala S, Thompson JF, Smithers BM, et al. Locoregional disease control in metastatic melanoma: exploratory analysis from phase 2 testing of intralesional rose bengal [abstract]. Eur J Cancer 2013;49:873-4
   Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman H, Daniels GA, et al. CALM study: a phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol 2013;31:abstract TPS3128
   Google Scholar
• Kaufman HL, Andtbacka RH, Collichio FA, et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [abstract]. ASCO 2014;32:Suppl 5; abstract 9008a
   Google Scholar
• Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2014;32(5s Suppl):abstract 9029^
   Google Scholar
• Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol 2010;49:482-91
   PubMed Web of Science ®Google Scholar
• Shistik G, Prakash AV, Fenske NA, et al. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol 2007;6:830-2
   Google Scholar
• Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2012;30:1641-5
   PubMed Web of Science ®Google Scholar
• Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004;29:15-21
   PubMed Web of Science ®Google Scholar
• Quigley EA, Halpern AC. Microinvasive melanoma: cutaneous pharmacotherapeutic approaches. Am J Clin Dermatol 2013;14:125-37
   Google Scholar
• Junkins-Hopkins JM. Imiquimod use in the treatment of lentigo maligna. J Am Acad Dermatol 2009;61:865-7
   PubMed Web of Science ®Google Scholar
• Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 2012;35:716-20
   PubMed Web of Science ®Google Scholar
• Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 2001;145:385-405
   PubMed Web of Science ®Google Scholar
• van der Steen PH, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin 1993;11:619-22
   PubMed Web of Science ®Google Scholar
• Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol 2007;56:869-71
   PubMed Web of Science ®Google Scholar
• Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 2014;109:308-13
   PubMed Web of Science ®Google Scholar
• Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009;50:266-71
   PubMed Web of Science ®Google Scholar
• Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Am J Clin Dermatol 2011;12:403-4
   PubMedGoogle Scholar
• Hinz T, Ehler LK, Bieber T, et al. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone. Eur J Dermatol 2013;23:532-3
   PubMedGoogle Scholar
• Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. Ann Dermatol 2012;24:373-5
   PubMed Web of Science ®Google Scholar
• Sowden J, Paramsothy Y, Smith AG. Malignant melanoma arising in the scar of lupus vulgaris and response to treatment with topical azelaic acid. Clin Exp Dermatol 1988;13:353-6
   Google Scholar
• Nazzaro-Porro M, Passi S, Zina G, et al. Effect of azelaic acid on human malignant melanoma. Lancet 1980;1:1109-11
   Google Scholar
• Nazzaro-Porro M, Breathnach AS, Balus L, et al. A case of recurrent (following surgery x2) invasive malignant melanoma with satellitosis (stage IIIA) successfully resolving after azelaic acid treatment administered by several routes. Clin Exp Dermatol 1996;21:321-3
   Google Scholar
• Schallreuter KU, Wood JM, Mensing H, Breitbart EW. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:167-71
   Google Scholar
• Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003;13:59-66
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Deraffele G, Mitcham J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005;115:1903-12
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Allen KO, Carlisle RR, et al. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005;11:4168-75
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31:520-7
   PubMed Web of Science ®Google Scholar
• Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003;63:8466-75
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu J, Sheng X, et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 2007;120:2418-25
   PubMed Web of Science ®Google Scholar
• Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8
   PubMed Web of Science ®Google Scholar
• Truchetet F, Heid E, Friedel J, et al. D.N.C.B. for malignant melanoma: significance in the treatment strategy. Anticancer Res 1989;9:1531-6
   Google Scholar
• Illig L, Paul E, Bodeker RH. Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years). Anticancer Res 1984;4:293-8
   Google Scholar
• Terheyden P, Kortum AK, Schulze HJ, et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol 2007;133:437-44
   PubMedGoogle Scholar
• Ryan RF, Krementz ET, Litwin MS. A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol 1988;38:250-6
   Google Scholar
• Rapprich H, Hagedorn M. Intralesional therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges 2006;4:743-6
   Google Scholar
• Ikic D, Spaventi S, Padovan I, et al. Local interferon therapy for melanoma patients. Int J Dermatol 1995;34:872-4
   Google Scholar
• Ikic D, Nola P, Maricic Z, et al. Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1981;1:1022-4
   Google Scholar
• von Moos R, Schaffner R, Cathomas R, et al. Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication. J Immunother 2010;33:92-5
   Google Scholar
• von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071-4
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990;95:180S-4S
   Web of Science ®Google Scholar
• Karakousis CP, Douglass HO Jr, Yeracaris PM, et al. BCG immunotherapy in patients with malignant melanoma. Arch Surg 1976;111:716-18
   PubMedGoogle Scholar